Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR6390 and Famitinib in Advanced HR+/HER2- Breast Cancer
NCT04733417Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib and famitinib in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate up to 30 months. Status: unknown.
02
Drugs
dalpiciclibfamitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04733417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04733417.